OncoMatch/Clinical Trials/NCT06732492
RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
Is NCT06732492 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies RD13-02 cell infusion for nk t-cell lymphoma.
Treatment: RD13-02 cell infusion — This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 Chimeric Antigen Receptor-T(CAR-T) therapy for patients with CD7-positive relapsed or refractory natural killer/T cell lymphoma, and to evaluate the pharmacokinetics of CD7 CAR-T in patients。
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Biomarker criteria
Required: CD7 positive expression (positive)
CD7 positive expression
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: anticancer therapy
Exception: before CAR-T infusion
Subjects with some anticancer therapy before CAR-T infusion will be excluded.
Lab requirements
Blood counts
Bone marrow lymphoblasts ≥5% by morphologic evaluation at screening
Kidney function
Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min
Liver function
Serum alanine aminotransferase(ALT)/aspartate aminotransferase(AST) < 3×upper limit of normal, Total bilirubin < 1.5×upper limit of normal or ≤1.5mg/dl
Cardiac function
Left ventricular ejection fraction ≥ 50%
Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min, Serum alanine aminotransferase(ALT)/aspartate aminotransferase(AST) < 3×upper limit of normal, Total bilirubin < 1.5×upper limit of normal or ≤1.5mg/dl; Left ventricular ejection fraction ≥ 50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06732492 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anticancer therapy disqualifies patients from enrollment.
Does this trial require CD7?
Yes, CD7 positive expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger and at least 3 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify